started · updated
PepGen announces $125 million public offering
PepGen, a clinical-stage biotechnology company, has priced a public offering of 25 million common shares at $5 per share. The offering is expected to generate gross proceeds of $125 million before underwriting discounts and expenses.
The company has granted underwriters a 30-day option to purchase up to 3.75 million additional shares, which could increase the total gross proceeds to $143.75 million. PepGen intends to use the net proceeds to fund the clinical development of its product candidate, PGN-EDODM1, an investigational treatment for myotonic dystrophy type 1. The company also plans to use the funds for working capital and general corporate purposes.
This financing follows positive Phase 2 results from the FREEDOM2-DM1 study. The offering is expected to close on or about November 13, subject to customary closing requirements.
Entities
Guggenheim Securities · H. C. Wainwright · Leerink Partners · Stifel